Pacific Biosciences of California, Inc. (PACB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 11.99 |
| Open | 11.76 |
| Bid | 11.56 x 1200 |
| Ask | 11.78 x 2200 |
| Day's Range | 11.48 - 12.09 |
| 52 Week Range | 3.85 - 14.20 |
| Volume | |
| Avg. Volume | 4,628,531 |
| Market Cap | 2.664B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PACB
Related Research
- Pacific Biosciences of CalifornDaily – Vickers Top Buyers & Sellers for 01/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Simply Wall St.
Pacific Biosciences of California (NASDAQ:PACB) shareholder returns have been massive, earning 313% in 5 years
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...
- PR Newswire
Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by PacBio. Before deducting t
- PR Newswire
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock, at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions and there can be no assur
